A review on genetic polymorphism in MTHFR gene with Down syndrome and leukemia

Down syndrome (DS), also called trisomy 21, has been predicted as leukemia endorsing syndrome. Due to the presence of notable clinical conditions, difference in treatment responses are noticed in patients with DS compared to without DS. Methylenetetrahydrofolatereductase (MTHFR) gene polymorphism ha...

Full description

Saved in:
Bibliographic Details
Published in:Meta Gene 2020-09, Vol.25, p.100752, Article 100752
Main Authors: Murugesan, Loganathan, Babu, Kavipriya, Puthamohan, Vinayaga Moorthi, Basavaraju, Preethi, Devaraj, Ilakkiyapavai, Balasubramani, Rubadevi, Moosa, Harsha Raziyabi Abdul Nazer, Kathiresan, Divya Sri, Pemula, Gowtham Danaiah, Sivakumar, Utthameshwaran, Magendhiran, Anandha Kumar
Format: Article
Language:English
Subjects:
A1298C
C677T
Down syndrome
Leukemia
MTHFR gene
Polymorphism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Down syndrome (DS), also called trisomy 21, has been predicted as leukemia endorsing syndrome. Due to the presence of notable clinical conditions, difference in treatment responses are noticed in patients with DS compared to without DS. Methylenetetrahydrofolatereductase (MTHFR) gene polymorphism has been witnessed in DS, leukemia and various genetic disorders/diseases. Particularly, C677T and A1298C polymorphism in MTHFR gene, which is responsible for the folate metabolism, lead to reduced enzyme activity and thus accumulate the methy-THF. It has been noticed that the polymorphism had impact on the genomic instability that causes leukemia. In the present review, —, we — are bring together the significance of genotypes of MTHFR gene and its relationship in DS and Leukemia patients as risk factor. It unravel the genotypes importance in disease diagnosis as well as polymorphism based therapeutic managements.
ISSN:2214-5400
2214-5400
DOI:10.1016/j.mgene.2020.100752